Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

ONCBeiGeneFinished

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · HNSCC for Phase 2 Dose Expansion · NSCLC for Phase 2 Dose Expansion

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Aug 3, 2026 · was worth 5, fading over time

    +1.7
Worry score2

Score over time

Stage
Phase 1/2
Patients
147 (final count)
Started
Nov 13, 2018
Main results expected
Feb 6, 2025
Fully finished
Feb 6, 2025
Results posted
Apr 2, 2026

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Measured over: Up to 30 days after last dose of study drug (maximum treatment duration: up to 32.7 months)

  • Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With Tislelizumab

    Measured over: Up to 28 days

  • Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With Tislelizumab

    Measured over: Up to 28 days

  • Phase 2 (Safety Lead-In): Number of Participants With TEAEs and SAEs

    Measured over: Up to 30 days after last dose of study drug (maximum duration of treatment: up to 19.6 months in Cohort A and up to 21.5 months in Cohort B)

  • Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Tislelizumab

    Measured over: Up to 21 days

  • Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and Tislelizumab

    Measured over: Up to 21 days

  • Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and Tislelizumab

    Measured over: Up to 21 days

  • Phase 2 (Dose Expansion): Overall Response Rate (ORR)

    Measured over: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to11.3 months, Cohort 5: up to 15.9 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT03744468 · record last updated 2026-04-02 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT03744468) ↗